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INTRODUCTION
Insulinoma is a tumor characterized by excessive
endogenous insulin secretion resulting in severe
hypoglycemia (1, 2). Surgical resection of insuli-
noma causes deterioration of the plasma glucose
level due to dramatic change of the insulin level by
removing the tumorous source of excessive insulin
production. Surgical stress is also well known to in-
crease the plasma glucose level due to an increase in
endogenous glucose production. It is, therefore, im-
portant to prevent hyperglycemia and hypoglycemia
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during and after resection of insulinoma.
Recently, perioperative glycemic control using an
artificial endocrine pancreas was reported (3-6).
However, the use of the artificial endocrine pancreas
in the perioperative period of pancreatic surgery has
yet to spread widely or become established in Japan.
We could successfully control and manage hypo-
glycemia and stress-induced hyperglycemia through-
out the procedure, as well as hyperglycemic re-
bound after removal of the tumor, using an artificial
endocrine pancreas.
CASE REPORT
A 71-year-old woman with insulinoma underwent
laparoscopic enucleation of insulinoma, along with
the use of an artificial endocrine pancreas (STG-22,
Nikkiso Co., Ltd., Tokyo, Japan). Her height and
body weight were 150 cm and 64.6 kg. She had an
episode of syncope due to hypoglycemia of 27 mg/
dl. Even though her blood glucose level dropped
below 40 mg/dl, she had no symptoms of hypogly-
cemia, such as sweating palpitation or general fa-
tigue. Insulinoma was strongly suspected from high
immunoreactive insulin (IRI) of 17.2 μU/ml during
typical hypoglycemia of 35 mg/dl. Dynamic abdomi-
nal computed tomography scan demonstrated a
hypervascular tumor of 12 mm diameter in the head
of the pancreas. Selective arterial calcium injection
into the gastroduodenal artery markedly increased
serum IRI levels, suggesting the localization of in-
sulinoma in the head of the pancreas.
After admission, blood glucose was monitored fre-
quently to avoid hypoglycemia. Before the induc-
tion of anesthesia, peripheral venous access was
established and initial vital monitoring was started
using electrocardiogram, pulse oximeter and non-
invasive blood pressure. Anesthesia was induced
with propofol, remifentanil and rocuronium bro-
mide and maintained with air, oxygen, sevoflurane
(1.0-2.0%), remifentanil (0.1-0.5 μg/kg/min) and
rocuronium bromide. Then, the radial artery was
catheterized to monitor arterial blood pressure and
STG-22 was employed. The target concentration of
blood glucose was set at 80-120 mg/dl during sur-
gery. Intraoperative blood glucose level was moni-
tored with STG-22 continuously and also checked
every 30 minutes by another strategy.
At the beginning of laparoscopic surgery, blood
glucose level was 105 mg/dl. When insulinoma was
detected and enucleated under ultrasound guidance,
the blood glucose level did not decrease in spite of
tumor manipulation. Until removal of the tumor, the
blood glucose level remained at around 80-100 mg/
dl. Soon after resection of the mass, the blood glu-
cose level was 80 mg/dl, but it gradually increased,
which is a typical reaction after the removal of a
tumor (hyperglycemic rebound) (Figure). However,
it was kept in the normal range by exogenous insu-
lin infusion. The operation time was 3 hours and 8
minutes, and the anesthesia time was 4 hours and
18 minutes.
After surgery, STG-22 was continuously used to
control blood glucose until the next morning. The
target concentration of blood glucose was set at
Figure : Alteration of blood glucose and the infusion rates of glucose and insulin in a patient with insulinoma treated using an artificial
endocrine pancreas during and after surgery
BG : blood glucose, GIR : glucose infusion rate, IIR : insulin infusion rate
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100-140 mg/dl after surgery. The glucose concen-
tration increased to around 200 mg/dl in the ICU,
but immediate administration of insulin suppressed
the severe hyperglycemia. With the reduction in
glucose concentration, the insulin infusion rate de-
creased and glucose infusion was started to avoid
hypoglycemia (Figure). The perioperative course
was uneventful. The artificial pancreas was shown
to be safe and efficient in a patient with insulinoma
during and after surgery.
DISCUSSION
Insulinoma is an endocrine tumor of the pancre-
atic β cells that is characterized by excessive endo-
genous insulin secretion resulting in severe hypo-
glycemia and unconsciousness. The incidence of
insulinoma in the general population is about one to
four per one million person-years. It is generally
solitary and smaller than 2 cm in more than 90% of
cases (1, 2). Surgical management especially enu-
cleation is the first choice for insulinoma. However,
in the case of malignancy or multiple tumors, pro-
gressive distal resection is required. After surgical
resection (distal pancreatectomy) of the pancreas,
8-23% of patients develop pancreatogenic diabetes,
which increases to 40-50% during follow-up (7).
The most important point in anesthetic manage-
ment of insulinoma resection is perioperative gly-
cemic control. The fluctuation of perioperative blood
glucose during the resection of insulinoma is very
intense. Until removal of the tumor, the blood glu-
cose level tends to decrease. On the other hand,
after removal of the tumor, blood glucose levels
sometimes tend to increase (called hyperglycemic
rebound) (8, 9). This was also observed in our pa-
tient. In addition, the postoperative blood glucose
fluctuation is also very intense. In our case, the
blood glucose level started to increase in the ICU,
but only to a maximum of 200 mg/dl, and the level
was controlled by appropriate insulin administration.
Subsequently, the blood glucose level began to de-
crease, but hypoglycemia was avoided by appropri-
ate glucose administration (minimum blood glucose
value : around 75 mg/dl). In the ICU in particular,
sudden glycemic control is critical, and use of a mild
control algorithm is necessary.
We report a case of insulinoma in which an ar-
tificial endocrine pancreas was used during and
after surgery. Intraoperative glucose management
during resection of pancreas (7, 10, 11) or total
pancreatectomy (7, 12) using an artificial endocrine
pancreas has previously been reported ; however,
there are extremely few reports of the use of an ar-
tificial endocrine pancreas in perioperative care of
insulinoma (13, 14). Pulver et al. (13) reported a
case which artificial beta cell (Biostator, Miles Labo-
ratories, Elkhart, IN) was utilized to maintain nor-
mal blood glucose in a patient who underwent par-
tial pancreatectomy for removal of an insulinoma.
However, this was reported a long time ago, it was
used only during surgery, and the device used is no
longer available. Manabe et al. (14) reported the an-
esthetic management of a 5-year-old patient with
insulinoma. They attempted continuous blood glu-
cose monitoring only using an artificial endocrine
pancreas (STG-22), and did not use a closed-loop
blood glucose control system. We performed not
only monitoring but also glycemic control by auto-
matic injection of glucose and insulin using a closed-
loop system during and after surgery.
The human brain primarily uses glucose as its
source of energy. Under normal conditions, the
brain is unable to synthesize or store glucose and is
thus exquisitely vulnerable to glucose deprivation
(15). In the 1930s, Manfred Sakel introduced hypo-
glycemia as a therapy in psychiatry, as reported in
the English literature in the late 1930s. From the
treatment, it was discovered that, if a patient re-
mained in a coma for longer than 30 minutes, the
coma would be irreversible (16). A flat electroen-
cephalogram was seen at blood glucose levels of 20
mg/dl or less (17). After 30-60 minutes of isoelec-
tricity, neuronal damage develops in selective brain
areas such as the cortex, the hippocampus and the
caudoputamen, while other areas like the cerebellum
and the brainstem are more resistant (18). Although
the mechanisms underlying this selective vulner-
ability to hypoglycemic damage are unknown, an
association with oxidative stress has recently been
suggested (19). Anesthesiologists must avoid hypo-
glycemia during surgery.
On the other hand, stress-induced hyperglycemia
and hyperglycemic rebound after the removal of
tumor often occur during the resection of insuli-
noma. In addition, elevation of insulin resistance
evoked by typical hyperinsulinemia and reduction of
pancreatic parenchyma leads to postoperative hyper-
glycemia. Hyperglycemia can worsen a number of
perioperative problems, including cardiac, neurologic
and infectious complications (20). Prevention of hy-
perglycemia during and after surgery is also very
important for patients with insulinoma.
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To avoid hypo- or hyperglycemia, frequent moni-
toring of the blood glucose level is necessary during
the resection of insulinoma. However, it is difficult
to detect glycemic disorder from symptoms such
as tachycardia or diaphoresis during anesthesia. It
is thus ideal to use an artificial endocrine pancreas.
In December 2007, our clinical team at Tokushima
University initiated a clinical trial to evaluate the
efficacy of the artificial endocrine pancreas for in-
traoperative patients (5). In this case, we used STG-
22, which is a bedside-type artificial endocrine pan-
creas (3, 4). The Nikkiso Company developed the
STG-22 unit in 1984 as an artificial endocrine pan-
creas, which was only a single device with a closed-
loop system. Peripheral venous blood for glucose
monitoring was sampled continuously at 2 ml/h.
STG-22 is capable of measuring the blood glucose
level continuously with its glucose sensor, and auto-
matically infuses insulin and/or glucose to adjust
the blood glucose level in accordance with a target
glucose value, which is called a closed-loop system.
The perioperative accuracy and reliability of continu-
ous blood glucose monitoring during use of an ar-
tificial pancreas have been established, both intraop-
eratively (21) and postoperatively (22). In this case,
STG-22 was shown to be safe and efficient in a pa-
tient with insulinoma during and after surgery, simi-
larly to other reports.
The merits of closed-loop intensive insulin ther-
apy using the artificial endocrine pancreas are the
possibility of strict glycemic control, an absence of
hypoglycemic attacks, reduced workload in spite of
frequent blood glucose measurements, and a reduc-
tion in incidents. On the other hand, the demerits
are high cost, problems associated with an insuffi-
cient quantity of blood obtained for monitoring, the
need for a long preparation time, difficulty of op-
eration, and limited duration of use, among others.
However, we believe that an artificial pancreas will
become a standard modality to achieve glycemic
control in patients who need strict and safe glyce-
mic control. Establishment of a new perioperative
blood glucose control method with the aid of an
artificial endocrine pancreas is urgently needed.
In conclusion, we used an artificial endocrine pan-
creas for insulinoma enucleation. The artificial en-
docrine pancreas (STG-22) was useful to monitor
and maintain blood glucose levels during and after
removal of the insulinoma without any hyper- or
hypoglycemia.
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